Bright Minds Biosciences Inc. (DRUG) has been able to initiate its phase 2 BREAKTHROUGH study using its 5-HT2C agonist BMB-101 for the treatment of adult patients with classic Absence Epilepsy and ...
Since 1983, eight new AEDs have been introduced (see Table 2 below). Sadly, a recent VA study of more than 21,000 subjects aged 65 years and older revealed that 80% were being treated with ...
Verywell Health on MSN
What causes seizures in adults for the first time
Medically reviewed by Smita Patel, DO Key Takeaways New-onset adult seizures may be due to stroke, high blood sugar, alcohol use or withdrawal, and several other medical conditions.If you had a ...
This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...
Add Yahoo as a preferred source to see more of our stories on Google. (NewsNation) — March 26 is Purple Day, a day dedicated to raising awareness about epilepsy worldwide. An estimated 50 million ...
CHARLOTTESVILLE, Va. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cavion, Inc., a clinical stage biotechnology company developing novel therapeutics for neurological diseases, announced today that their first ...
Bright Minds Biosciences (DRUG) added ~10% in the premarket on Tuesday after the company said that its lead asset, BMB-101, succeeded in a mid-stage trial for adults with Absence Seizures and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results